Home > Publications : Drug Bulletin
ACCC's Compendia-Based Drug Bulletin
ACCC's Compendia–Based Drug Bulletin is no longer published. For two decades it was the standard reference for oncology reimbursement. Currently, under revisement, a new drug guide will be available in 2010.
Issues from 2002-2008 are archived and available online.
ACCC's Compendia-Based Drug Bulletin is NOT a Medicare-recognized compendium.
20082007
Compendia-Based Drug Bulletin, August 2007 – Vol. 16, No. 3
Compendia-Based Drug Bulletin, May 2007 – Vol. 16, No. 2
Compendia-Based Drug Bulletin, February 2007 – Vol. 16, No.1
2006
Compendia-Based Drug Bulletin, November 2006 – Vol. 15, No. 4
Compendia-Based Drug Bulletin, August 2006 – Vol. 15, No. 3
Compendia-Based Drug Bulletin, May 2006 – Vol. 15, No. 2
Compendia-Based Drug Bulletin, February 2006 – Vol. 15, No. 1
2005
Compendia-Based Drug Bulletin, November 2005 – Vol. 14, No. 4
Compendia-Based Drug Bulletin, August 2005 – Vol. 14, No. 3
Compendia-Based Drug Bulletin, May 2005 Update – Vol. 14 No.2
Compendia-Based Drug Bulletin, February 2005 Update – Vol. 14 No.1
2004
Compendia-Based Drug Bulletin, November 2004 Update – Vol. 13 No.4
Compendia-Based Drug Bulletin, August 2004 Update – Vol. 13 No.3
Histamine Dihydrochloride (Ceplene) was incorrectly listed in this issue. Ceplene has been FDA approved as an investigational drug and is currently in Phase 3 clinical trials.
Compendia-Based Drug Bulletin, May 2004 Update – Vol. 13 No. 2
Please note: Doxorubicin Liposomal (Doxil) is indicated for Breast. This indication was inadvertently left out of the May 2004 issue. Please note: The exact wording for the US Pharmacopeia's new indication for Rituximab should read: Re-Induction treatment of Indolent Non-Hodgkin's Lymphoma. The off-label use for Thalidomide in myelodysplastic syndromes was inaccurately reported on the US Pharmacopeia’s web site, and subsequently in ACCC’s February Compendia-based Drug Bulletin. Thalidomide was voted "Acceptance not established" by USP medical experts for myelodysplastic syndromes. Both USP and ACCC regret any inconvenience this has caused. The May Drug Bulletin reflects corrected USP information.
Compendia-Based Drug Bulletin, February 2004 Update – Vol. 13 No. 1
2003
Compendia-Based Drug Bulletin, November 2003 Update - Vol. 12 No. 4
Compendia-Based Drug Bulletin, August 2003 Update – Vol. 12 No. 3
Compendia-Based Drug Bulletin, May 2003 Update – Vol. 12 No. 2
Compendia-Based Drug Bulletin, February 2003 Update – Vol. 12 No. 1
Please note: The prices for Darbopoetin Alfa were incorrect in the print edition of the February 2003 Bulletin. They are correct in this PDF version.
2002
Compendia-Based Drug Bulletin, November 2002 Update – Vol. 11 No. 4
Compendia-Based Drug Bulletin, August 2002 Update – Vol. 11 No. 3
Please Note: The exact wording for the new indication for Amifostine (Ethyol) is "Reduction in the incidence of mucositus in patients receiving radiation therapy or radiation combined with chemotherapy." Coding should be 288.0, V58.0, V58.1
Compendia-Based Drug Bulletin, May 2002 Update - Vol. 11 No.2
As of January 1, 1996, the American Medical Association no longer updates or publishes its Drug Evaluations. AMA transferred its Drug Evaluations' files to the United States Pharmacopeial Convention, Inc.
Facebook
LinkedIn
Twitter
ACCCExchange Listserve